论文部分内容阅读
孕激素治疗子宫内膜癌并不是一个新方法。因为孕酮对增生的子宫内膜有促其转化为分泌期的作用,而内膜增生又和内膜癌的发病有一定因果关系。早在40年代已有人试用黄体酮治疗内膜癌,但因为药物作用太弱而未获代功。至50年代,人工合成的高效孕激素类药物相继问世。这些药物在避孕方面显示出强大的孕酮作用,提醒人们用于宫内膜癌的治疗可能有效。1960年Kelly 和Baker 首次报道以己酸孕酮治疗转移性子宫内膜癌22例,其中7例可以观察到肿瘤有消退现象,从而奠定了宫内膜癌激素治疗的基础。一、作用机制一般认为在药物作用下,子宫内膜癌可以发生从恶性向正常子宫内膜转化的现象,表
Progestin treatment of endometrial cancer is not a new method. Because progesterone on proliferation of endometrial have prompted its conversion to the role of secretory phase, and intimal hyperplasia and endometrial cancer have a causal relationship. As early as in the 1940s, progesterone has been tried in the treatment of endometrial cancer, but because of the drug’s effect is too weak and did not take the merit. By the 1950s, synthetic high-potency progesterone drugs came out one after another. These drugs show a strong progesterone effect in terms of contraception, reminding people that treatment for endometrial cancer may be effective. In 1960, Kelly and Baker first reported 22 cases of metastatic endometrial carcinoma with caproate, of which 7 cases could be observed tumor regression, which laid the foundation for hormone therapy of endometrial cancer. First, the mechanism of action Generally believed that the role of drugs, endometrial cancer can occur from malignant to normal endometrial transformation phenomenon